Fig. 4
Anti-TTx induces the expansion, differentiation and CTLA-4 expression in Her2/neu369–377 tumor specific CD8+ T cells. a. Representative contour plots of tetramer specific CD8+ T cells staining for HER2/neu369–377 (KIFGSLAFL), HER2/neu689–697 (RLLQETELV), HER2/neu435–443 (ILHNGAYSL) and NY-ESO 1157–165 (SLLMWITQV), and two tetramers for viral antigens (NLVPMVATV – CMVPP65, and GILGFVFTL – influenza M1 FLU58–66), stained ex vivo in PBMCs from a breast cancer patient before and after anti-TTx in purified CD8+ T cells. The number inside the plots represents the percentage of tetramer-specific CD8+ T cells. b. Representative contour plots of tetramer specific CD8+ T cells after 7 days of in vitro stimulation of PBMCs with the corresponding peptide pulsed 2d-aDCs, the number inside the plots represents the percentage of tetramer-specific CD8+ T cells. Results of experiments presented in panels a, and B are representative of two performed. c. and d. Representative pie charts of ex vivo (c) or after in vitro PBMC stimulation (d), as described in a and b, with the percentage of the phenotype of naïve and memory sub-populations in CD8+ tetramer positive T cells for four TAAs and two viral HLA-A*02:01 peptides before and after anti-TTx. Blue; naïve, Orange; TSCM, Grey; TCM, yellow; TEM; and green TEMRA. Results of experiments presented in panels c and d are representative of two performed. e. Representative contour plots of CTLA-4 vs CD8 in tetramer positive CD8+ T cells for HER2/neu369–377 (KIFGSLAFL) and NY-ESO1157–165 (SLLMWITQV) tetramer + CD8+ T cells for two viral antigens (NLVPMVATV – CMVPP65, and GILGFVFTL – influenza M1 FLU58–66), in PBMCs stimulated with in situ 2d-aDCs from PBMCs obtained before and after anti-TTx as described in a and b. Results of experiments presented are representative of two performed